Nephrol Dial Transplant (2004) 19: 561-565
Nephrol Dial Transplant Vol. 19 No. 3 (c) ERA-EDTA 2004; all rights reserved
Original Article
Labile iron in parenteral iron formulations: a quantitative and comparative study
1University of Arizona College of Medicine, Tucson and 2J2 Laboratories, Tucson, AZ, USA
Correspondence and offprint requests to: David B. Van Wyck, MD, Kidney Health Institute, LLC, 6720 N. Nanini Drive, Tucson, AZ 85704, USA. Email: dvanwyck{at}sprynet.com
Background. Evidence of iron-mediated oxidative stress, neutrophil dysfunction and enhanced bacterial growth after intravenous (IV) iron administration has been ascribed to a labile or bioactive iron fraction present in all IV iron agents.
Methods. To quantify and compare the size of the labile fraction in several classes of IV iron agents, we examined iron donation to transferrin (Tf) in vitro. We added dilutions of ferric gluconate, iron sucrose and each of two iron dextran preparations to serum in vitro, passed the resulting samples through alumina columns to remove iron agent and free organic iron, and measured Tf-bound iron in the resulting eluates. Comparing results to serum samples without added iron, we calculated delta Tf-bound iron for each agent at each concentration. Finally, we compared delta Tf-bound iron to the concentration of added agent and calculated the percent iron donation to Tf.
Results. We found that Tf-bound iron increased with added iron concentration for each agent: delta Tf-bound iron was directly related to the concentration and type of iron agent (P<0.001). Mean percent iron donation to Tf ranged from 2.5 to 5.8% with the following progression: iron dextran-Dexferrum®<iron dextran-INFeD®<iron sucrose<ferric gluconate. Pairwise differences between agents for percent iron donation were statistically significant (P<0.05) only between ferric gluconate and both iron dextran agents, and between iron sucrose and iron dextran-Dexferrum®.
Conclusions. Approximately 2–6% of total iron in commonly used IV iron compounds is available for in vitro iron donation to Tf. This fraction may contribute to evidence of bioactive iron in patients after IV iron administration.
Keywords: adverse effects; ferric gluconate; iron; iron dextran; iron sucrose; transferrin
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Provenzano, B. Schiller, M. Rao, D. Coyne, L. Brenner, and B. J.G. Pereira Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients Clin. J. Am. Soc. Nephrol., February 1, 2009; 4(2): 386 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Smith, G. M. Balanos, Q. P. P. Croft, N. P. Talbot, K. L. Dorrington, P. J. Ratcliffe, and P. A. Robbins The increase in pulmonary arterial pressure caused by hypoxia depends on iron status J. Physiol., December 15, 2008; 586(24): 5999 - 6005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Kovesdy, G. H. Lee, and K. Kalantar-Zadeh Serum Ferritin: Deceptively Simple or Simply Deceptive? Lessons Learned From Iron Therapy in Patients With Chronic Kidney Disease Journal of Pharmacy Practice, December 1, 2008; 21(6): 411 - 419. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Wang, G. Geraci, M. K. Kuhlmann, N. W. Levin, and G. J. Handelman Chemical reactions of vitamin C with intravenous-iron formulations Nephrol. Dial. Transplant., January 1, 2008; 23(1): 120 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Handelman Vitamin C deficiency in dialysis patients--are we perceiving the tip of an iceberg? Nephrol. Dial. Transplant., February 1, 2007; 22(2): 328 - 331. [Full Text] [PDF]
|
|
|
|
|
|
K. Bishu and R. Agarwal Acute Injury with Intravenous Iron and Concerns Regarding Long-Term Safety Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(Supplement_1): S19 - S23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kalantar-Zadeh, D. L. Regidor, C. J. McAllister, B. Michael, and D. G. Warnock Time-Dependent Associations between Iron and Mortality in Hemodialysis Patients J. Am. Soc. Nephrol., October 1, 2005; 16(10): 3070 - 3080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Drueke and Z. A. Massy Intravenous Iron: How Much Is Too Much? J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2833 - 2835. [Full Text] [PDF]
|
|
|
|
|
|
B. G. Danielson Structure, Chemistry, and Pharmacokinetics of Intravenous Iron Agents J. Am. Soc. Nephrol., December 1, 2004; 15(suppl_2): S93 - S98. [Full Text] [PDF]
|
|
|
|
|
|
D. B. Van Wyck Labile Iron: Manifestations and Clinical Implications J. Am. Soc. Nephrol., December 1, 2004; 15(suppl_2): S107 - S111. [Full Text] [PDF]
|
|
|
|
|
|
D. W. Coyne Labile iron in parenteral iron formulations: a quantitative and comparative study Nephrol. Dial. Transplant., October 1, 2004; 19(10): 2674 - 2675. [Full Text] [PDF]
|
|
|
|
|
|
D. B. Van Wyck Reply Nephrol. Dial. Transplant., October 1, 2004; 19(10): 2675 - 2676. [Full Text] [PDF]
|
|